Analysis Tools
mortality/aging
|
• 10 of 19 mice die by 20 months of age
|
homeostasis/metabolism
|
• at 20 months of age
|
|
• on a normal salt diet
|
|
• in the kidney and urine but not brain or plasma
|
albuminuria
(
J:175630
)
|
• in angiotensin II-treated mice
|
|
• on a normal salt diet
|
|
• 15-fold in hydralazine-treated mice compared with 3-fold in similarly treated wild-type mice
|
|
• natriuresis and diuresis response to L-DOPA treatment is attenuated compared to in similarly treated wild-type mice
• angiotensin II-treated mice exhibit increased albuminuria and tubulointerstitial injury compared with similarly treated wild-type mice
|
renal/urinary system
|
• at 20 months of age
|
albuminuria
(
J:175630
)
|
• in angiotensin II-treated mice
|
|
• at 20 months of age, mice exhibit increased renal injury index with increased macrophage, neutrophil, and lymphocyte infiltration compared with wild-type mice
|
|
• in angiotensin II-treated mice
|
cardiovascular system
|
• at 20 months of age
|
|
• at 20 months of age
|
|
• by 3 months of age on a normal salt diet
• on a high salt diet for 4 weeks
• following angiotensin II exposure until day 5
• however, mice exhibit normal blood pressure on a low salt diet
|
immune system
|
• in angiotensin II-treated mice
|
cellular
|
• in response to a high salt diet as measured by urinary excretion of F2-isoprostane
• in angiotensin II-treated mice
|
growth/size/body
|
• at 20 months of age
|
|
• at 20 months of age
|
